To the best of our knowledge, only three studies have been published to date on HER2‐positive metastatic BC (HER2 + mBC), all with contrasting results8–10, and only one9 included findings on the newer anti‐HER2 drugs pertuzumab and trastuzumab emtansine (T‐DM1). Here, ERBB2 is linked to breast cancer.